白介素4在支气管哮喘发病机制中的作用及其靶向治疗研究  

Function and targeted therapy of interleukin-4 in bronchial asthma

作　　者：杨学敏[1] 史海广[1] 成家军[1] 李志奎[1] 

机构地区：[1]第四军医大学西京医院呼吸内科,西安710032

出　　处：《中华哮喘杂志（电子版）》2011年第2期30-34,共5页Chinese Journal of Asthma(Electronic Version)

摘　　要：支气管哮喘(简称哮喘)发病率正逐年上升,其发病机制十分复杂。目前认为Th1/Th2反应失衡导致Th2细胞增多是其重要的发病机制之一,其中Th2细胞产生的细胞因子白介素4在哮喘发病中起重要的作用,成为新的哮喘治疗靶点。The incidence of bronchial asthma（asthma）is increasing year by year,besides,the pathogenesis is very complex.Nowadays,it is believed that imbalance of Th1/Th2 response leading to excessively create of Th2 cells is one of the important pathogenesis.IL-4 produced by Th2 cells play an important role in asthma,understanding IL-4 in asthma may lead to new target to therapy in the future.

关 键 词：哮喘 白介素4 靶向治疗 

分 类 号：R562.25[医药卫生—呼吸系统]